Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

K. Fizazi, N. Shore, M. Smith, J. Carles, T. Lebret, V. Lietuvietis, H. Mahammedi, A. Rannikko, E. Vjaters, P. Werbrouck, M. Miskic, I. Kuss, M. Le Berre, G. Borghesi, T. Sarapohja, S. Fayerabend

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article numberP1226
Pages (from-to)S1740-S1741
Number of pages2
JournalEuropean Urology
Issue numberSupplement 1
Publication statusPublished - Jun 2021
Externally publishedYes
Event36th Annual European Association of Urology (EAU) Congress - Virtual
Duration: 8 Jul 202113 Jul 2021
Conference number: 36

Field of Science*

  • 3.2 Clinical medicine
  • 3.1 Basic medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this